Sera Prognostics (NASDAQ:SERA) Shares Break Above Fifty Day Moving Average Following Weak Earnings

Sera Prognostics, Inc. (NASDAQ:SERA)’s stock price passed above its 50-day moving average during trading on Thursday following a better than expected earnings announcement. The stock has a 50-day moving average of $2.04 and traded as high as $2.08. Sera Prognostics shares last traded at $2.08, with a volume of 21,631 shares trading hands.

The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Sera Prognostics had a negative net margin of 34,866.67% and a negative return on equity of 49.61%. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.07 million.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $5.50.

Insider Buying and Selling at Sera Prognostics

In other news, CEO Zhenya Lindgardt sold 20,139 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $2.00, for a total transaction of $40,278.00. Following the sale, the chief executive officer directly owned 844,870 shares in the company, valued at approximately $1,689,740. The trade was a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 39,661 shares of company stock worth $79,563. 11.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SERA. Sanders Morris Harris LLC bought a new position in Sera Prognostics in the third quarter worth $642,000. AWM Investment Company Inc. acquired a new stake in Sera Prognostics during the second quarter worth $377,000. Arkadios Wealth Advisors acquired a new stake in Sera Prognostics during the first quarter worth $25,000. Finally, Segall Bryant & Hamill LLC bought a new stake in Sera Prognostics in the 1st quarter valued at $193,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Sera Prognostics Trading Up 3.0%

The stock has a market cap of $82.06 million, a P/E ratio of -3.10 and a beta of 1.14. The company’s fifty day simple moving average is $2.04 and its 200-day simple moving average is $2.12.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a women’s health diagnostics company focused on improving pregnancy outcomes through biomarker-based testing. The company uses proteomics, bioinformatics and clinical data to develop diagnostic and prognostic products designed to identify risks associated with pregnancy complications.

Its lead product is the PreTRM test, a blood-based test intended to assess a pregnant woman’s risk of spontaneous preterm birth in a singleton pregnancy. The test measures specific protein biomarkers and is designed to provide physicians with information that may support risk assessment, patient management and care planning during pregnancy.

Founded in 2008 and headquartered in Salt Lake City, Utah, Sera Prognostics primarily serves the U.S.